Bedell Frazier Investment Counselling LLC Has $831,000 Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Bedell Frazier Investment Counselling LLC reduced its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 19.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,113 shares of the company’s stock after selling 5,244 shares during the quarter. Bedell Frazier Investment Counselling LLC’s holdings in CRISPR Therapeutics were worth $831,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. Highline Wealth Partners LLC acquired a new stake in CRISPR Therapeutics during the 4th quarter worth $39,000. Western Pacific Wealth Management LP raised its position in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after acquiring an additional 500 shares during the last quarter. Spire Wealth Management lifted its stake in shares of CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after purchasing an additional 1,482 shares during the period. Finally, MCF Advisors LLC acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $80,000. Institutional investors own 69.20% of the company’s stock.

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director John Greene acquired 7,000 shares of the firm’s stock in a transaction dated Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, with a total value of $313,950.00. Following the transaction, the director now owns 7,000 shares in the company, valued at approximately $313,950. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 32,381 shares of company stock valued at $1,608,243. 4.10% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CRSP. Barclays raised their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Royal Bank of Canada lowered their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 12th. Truist Financial lifted their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. Finally, The Goldman Sachs Group lowered their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and an average price target of $73.11.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $36.99 on Monday. The stock has a market capitalization of $3.17 billion, a PE ratio of -8.46 and a beta of 1.77. The company’s 50-day moving average price is $43.10 and its two-hundred day moving average price is $45.17. CRISPR Therapeutics AG has a one year low of $36.25 and a one year high of $68.39.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.